-
公开(公告)号:US08183275B2
公开(公告)日:2012-05-22
申请号:US12311672
申请日:2007-10-16
申请人: Peter H. Dobbelaar , Christopher L. Franklin , Allan Goodman , Cheng Guo , Peter R. Guzzo , Mark Hadden , Shuwen He , Alan J. Henderson , Tianying Jian , Linus S. Lin , Jian Liu , Ravi P. Nargund , Megan Ruenz , Bruce J. Sargent , Iyassu K. Sebhat , Larry Yet
发明人: Peter H. Dobbelaar , Christopher L. Franklin , Allan Goodman , Cheng Guo , Peter R. Guzzo , Mark Hadden , Shuwen He , Alan J. Henderson , Tianying Jian , Linus S. Lin , Jian Liu , Ravi P. Nargund , Megan Ruenz , Bruce J. Sargent , Iyassu K. Sebhat , Larry Yet
IPC分类号: A61K31/4178 , A61K31/4164 , C07D471/04 , C07D401/10 , C07D403/10 , C07D233/64
CPC分类号: C07D401/10 , C07D233/64 , C07D403/10 , C07D403/12 , C07D405/04 , C07D409/10 , C07D413/06 , C07D417/06 , C07D417/10 , C07D471/04
摘要: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
-
32.
公开(公告)号:US08106070B2
公开(公告)日:2012-01-31
申请号:US12311541
申请日:2007-10-16
申请人: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M. -C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
发明人: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M. -C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
IPC分类号: A61K31/437 , A61K31/44 , A61K31/4178 , C07D401/10 , C07D231/02 , C07D471/04
CPC分类号: C07D401/10 , C07D233/64 , C07D401/14 , C07D403/10 , C07D417/10 , C07D471/04
摘要: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
摘要翻译: 某些新颖的取代的咪唑是人类bombesin受体的配体,特别是人类bombesin受体亚型-3(BRS-3)的选择性配体。 因此,它们可用于治疗,控制或预防对调节BRS-3的疾病和病症,例如肥胖症和糖尿病。
-
公开(公告)号:US20100204236A1
公开(公告)日:2010-08-12
申请号:US12311672
申请日:2007-10-16
申请人: Peter H. Dobbelaar , Christopher L. Franklin , Allan Goodman , Cheng Guo , Peter R. Guzzo , Mark Hadden , Shuwen He , Alan J. Henderson , Tianying Jian , Linus S. Lin , Jian Liu , Ravi P. Nargund , Megan Ruenz , Bruce J. Sargent , Iyassu K. Sebhat , Larry Yet
发明人: Peter H. Dobbelaar , Christopher L. Franklin , Allan Goodman , Cheng Guo , Peter R. Guzzo , Mark Hadden , Shuwen He , Alan J. Henderson , Tianying Jian , Linus S. Lin , Jian Liu , Ravi P. Nargund , Megan Ruenz , Bruce J. Sargent , Iyassu K. Sebhat , Larry Yet
IPC分类号: A61K31/4178 , A61K31/4985 , A61K31/501 , A61K31/497 , A61K31/506 , A61K31/4439 , A61K31/427 , A61K31/425 , A61K31/4196 , A61K31/4164 , C07D471/04 , C07D401/10 , C07D417/10 , C07D405/10 , C07D403/10 , C07D409/06 , C07D233/64 , A61P9/10 , A61P3/04
CPC分类号: C07D401/10 , C07D233/64 , C07D403/10 , C07D403/12 , C07D405/04 , C07D409/10 , C07D413/06 , C07D417/06 , C07D417/10 , C07D471/04
摘要: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
-
34.
公开(公告)号:US20100004280A1
公开(公告)日:2010-01-07
申请号:US12311541
申请日:2007-10-16
申请人: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.-C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
发明人: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Jian Liu , Michael M.-C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
IPC分类号: A61K31/437 , C07D401/10 , C07D231/02 , C07D471/04 , A61K31/44 , A61K31/4178 , A61P3/04
CPC分类号: C07D401/10 , C07D233/64 , C07D401/14 , C07D403/10 , C07D417/10 , C07D471/04
摘要: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
摘要翻译: 某些新颖的取代的咪唑是人类bombesin受体的配体,特别是人类bombesin受体亚型-3(BRS-3)的选择性配体。 因此,它们可用于治疗,控制或预防对调节BRS-3的疾病和病症,例如肥胖症和糖尿病。
-
-
-